THE ROLE OF LOW MOLECULAR WEIGHT METABOLITES OF THE INTESTINAL MICROBIOTA IN THE PATHOGENESIS, DIAGNOSIS AND PREVENTION OF COLORECTAL CANCER

The purpose of the study is to examine the content of short chain fatty acids (SCFA) in patients with colon cancer (CC) in the mucosa of the colon (CM) and feces by GLC-analysis: to assess their significance. Material and methods: the Study was performed in 52 patients operated on for colon cancer. Patients ranged in age from 61 to 81 years, 32 women and 20 men. In 14 cases the tumor was localized in the blind and ascending Department of the colon, 6 - in descending, 26- in the sigmoid colon, in 6 - in rectosigmoid part. In this regard, in 14 cases, the right hemicolectomy, 14 left hemicolectomy, 16 resection of the Sigma, 8 - anterior resection of the rectum. Histological examination revealed colon adenocarcinoma varying degrees of differentiation (high difference-25, moderate - -20, low of -7). Distribution of patients according to prevalence of tumor process was as follows: -2 I, IIA -4, -36 IIIA, IIIB -10. By GLC analysis to determine the content SCFA in CM and feces. Results: the Absolute contents SCFA in CM, the group of patients with CC tends to decrease compared to the control group. The total absolute concentration SCFA when the tumor in the right departments is higher in comparison with the concentration of SCFA when left-sided localization (0,420±0,110 mg/g and of 0.350±0.001 mg/g, respectively). In the study profiles in samples of tumor and feces when left localization of the significantly elevated level of propionic and butyric acids (up to 0,159±0,001 ed and 0,105±0,002 units, respectively, at a rate of 0,134±0,001 ed and 0,087±0,004 units, respectively, in CM; to 0,241±0,001 0,221 and u of±0.002 units, respectively, at a rate 0,189±0,001 ed and 0,176±0,004 units, respectively, in the feces), when right - level of isolated oil acid (0,093±0,011 u, at a rate of up to 0,067±0,01 IU per CM; to 0.281±0,002 units, at a rate of up to 0,176±0,004 ed feces). Among CC patients with increasing tumor stage marks an increase in the level of butyric acid (0,099±0,021 ed at T 1-3, to 0,110±0,030 ed at T4 in SOTK, 0,201±0,002 ed at T 1-3, to 0,220±0,002 ed at T4 in the feces) and increasing the ratio of isocyclic to acids in CM and feces (1,929±0,010 u at T 1-3, to 2,217±0,019 ed at T4 in CM, with 2,432±0,120 ed at T 1-3, to 4,327±0,110 units at T4 in feces). By reducing the degree of tumor differentiation (highly, moderately -, poorly-differentiated) in CM marked increase in the proportion of propionic (of 0.152±0,010 u, 0,209±0,01 units, 0,224±0,010 u, respectively) and mainly oil acid (of 0.085±0,010 units, 0,120±0,010 units, 0,168±0,010 units, respectively). The ratio of isocyclic forms to acids do not differ. Conclusion: in CC patients revealed specific changes SCFA in CM, depending on the localization, differentiation grade and depth of germination by the tumor of the intestinal wall is comparable to the change in feces. Changes SCFA in the stool can be used as a non-invasive test that allows indirectly to judge the presence of tumor, its localization and extent of germination of the bowel wall by the tumor. The use of preparations containing precursors of butyric acid (psyllium) or itself butyric acid, is a promising direction of CC canceroprevention.

microflora, of low molecular weight metabolites of the intestinal microbiota, short chain fatty acids (SCFA), colon cancer, butyric acid (butyrate), psyllium, butyrate+inulin

1. Шапошников А. В. Колоректальный рак. Канцерогенез и онкопревенция: пособие для врачей. - Москва: Форте принт, 2015.

2. Marta Borges-Canha, et al. Role of colonic microbiota in colorectal carcinogenesis: A systematic review. Rev Esp Enferm Dig (Madrid) Vol. 107, № 11, pp. 659-671, 2015.

3. Scott J. Bultman. Emerging roles of the microbiome in cancer. Carcinogenesis vol.35 №.2 pp.249-255, 2014.

4. Short Chain Fatty Acides.// Congress Short Report Falk Symposium, comp. by Scheppach W. - Strasbourg, 1993. - 50 p.

5. Siavoshian S. Et al. Butyrate and trichostatin A effects on the proliferation/differentiation of humen intestinal epithelial cells: induction of cyclin D 3 and p21 expression.// Gut. - 2000. - V.46. - Pp. 507-514.

6. Ардатская М. Д. Масляная кислота и инулин в клинической практике. Москва, Прима Принт, 2016.

7. Lupton, J. R. Microbial degradation products influence colon cancer risk: the butyrate controversy. 2004, J. Nutr., 134, 479-482.

8. Donohoe DR, et al. (2014) A Gnotobiotic Mouse Model Demonstrates That Dietary Fiber Protects against Colorectal Tumorigenesis in a Microbiota- and Butyrate-Dependent Manner. Cancer discovery 4(12):1387-1397.

9. Sebastian C & Mostoslavsky R (2014) Untangling the fiber yarn: butyrate feeds warburg to suppress colorectal cancer. Cancer discovery 4(12):1368-1370.

10. Scott J. Bultman. The Microbiome and Its Potential as a Cancer Preventive Intervention. Semin Oncol. 2016 Feb;43(1):97-106.

11. Головенко О. В., Халиф И. Л., Головенко А. О. Лечение заболеваний кишечника масляной кислотой. Поликлиника № 2, 2012.

12. Thangaraju M, et al. (2009) GPR 109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer research 69(7):2826-2832.

13. Singh N, Gurav A, Sivaprakasam S, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 2014;40:128-39. DOI: 10.1016/j.immuni.2013.12.007

14. Terzic J, Grivennikov S, Karin E, & Karin M (2010) Inflammation and colon cancer. Gastroenterology 138(6):2101-2114 e2105.

15. Itzkowitz SH & Harpaz N (2004) Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126(6):1634-1648.

16. Ардатская М. Д. Клиническое значение короткоцепочечных жирных кислот при патологии желудочно-кишечного тракта. Докторская диссертация, М., 299 с., 2003.

17. Иконников Н. С., Ардатская М. Д., Дубинин А. В., и др. Патент РФ «Способ разделения смеси жирных кислот фракции С2-С7 методом газожидкостной хроматографию». N 2145511 от 9.04.1999 г.

18. Осина В. А. Абсорбционная функция толстой кишки в норме и при патологии.// Экспериментальная и клиническая гастроэнтерология. - 2002. - № 1. - С. 81-85.

19. Emenaker N. J., Basson M. D. Short chain fatty acids differentially modulate cellular phenotype and c-myc protein levels in primary human nonmalignant and malignant colonocytes. Dig Dis Sci. 2001 Jan;46(1):96-105.

20. Emenaker N. J., Calaf G. M., Cox D, Basson M. D., Qureshi N. Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model. J Nutr. 2001 Nov;131 (11 Suppl): 3041S-6S.

21. Федоров Н. А. Циклические пуриновые нуклеотиды 3,5-АМФ и 3,5-ГМФ как факторы регуляции пролиферации и дифференцировки гемопоэтических клеток.//Успехи современной биологии, 1975, Т. 79, вып.2, с. 225-240.

22. De Rubertis F. R., Chayoth R, Field J. B. The content and metabolism of cyclic AMP and cyclic GMP in the adenocarcinoma of the human colon.//J.Clin.Invest.,1976, v.57, p.641-649.

23. Блохина Н. Г., Пискунова Т. В., Киркин Б. В., Чижиков Б. А. Исследование циклических нуклеотидов при раке, полипах толстой кишки и неспецифических колитах.//Вест. АМН СССР, 1985, № 3, с. 74-77.

24. Бышевский А. Ш., Терсенов О. А. Биохимия для врача. Екатеринбург, «Уральский рабочий», 1994.